Abstract
Aberrant expression and activation of receptor tyrosine kinases (RTK) is a frequent feature of tumor cells that may underlie tumor aggressiveness. Among RTK, Axl, a member of the Tyro3-Axl-Mer family, represents a potential therapeutic target in different tumor types given its over-expression which leads to activation of oncogenic signaling promoting cell proliferation and survival, as well as migration and invasion. Axl can promote aggressiveness of various cell types through PI3K/Akt and/or MAPK/ERK, and its expression can be transcriptionally regulated by multiple factors. Deregulated Axl expression and activation have been shown to be implicated in reduced sensitivity of tumor cells to target-specific and conventional antitumor agents, but the precise mechanism underlying these phenomena are still poorly understood. Several small molecules acting as Axl inhibitors have been reported, and some of them are undergoing clinical investigation. In this review, we describe Axl biological functions, its expression in cancer and in drug-resistant tumor cells and the development of inhibitors tailored to this receptor tyrosine kinase.
Keywords: Cancer, receptor tyrosine kinases, Axl, drug resistance, invasion, inhibitors.
Current Medicinal Chemistry
Title:Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
Volume: 23 Issue: 15
Author(s): Cristina Corno, Laura Gatti, Cinzia Lanzi, Nadia Zaffaroni, Diego Colombo and Paola Perego
Affiliation:
Keywords: Cancer, receptor tyrosine kinases, Axl, drug resistance, invasion, inhibitors.
Abstract: Aberrant expression and activation of receptor tyrosine kinases (RTK) is a frequent feature of tumor cells that may underlie tumor aggressiveness. Among RTK, Axl, a member of the Tyro3-Axl-Mer family, represents a potential therapeutic target in different tumor types given its over-expression which leads to activation of oncogenic signaling promoting cell proliferation and survival, as well as migration and invasion. Axl can promote aggressiveness of various cell types through PI3K/Akt and/or MAPK/ERK, and its expression can be transcriptionally regulated by multiple factors. Deregulated Axl expression and activation have been shown to be implicated in reduced sensitivity of tumor cells to target-specific and conventional antitumor agents, but the precise mechanism underlying these phenomena are still poorly understood. Several small molecules acting as Axl inhibitors have been reported, and some of them are undergoing clinical investigation. In this review, we describe Axl biological functions, its expression in cancer and in drug-resistant tumor cells and the development of inhibitors tailored to this receptor tyrosine kinase.
Export Options
About this article
Cite this article as:
Corno Cristina, Gatti Laura, Lanzi Cinzia, Zaffaroni Nadia, Colombo Diego and Perego Paola, Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells, Current Medicinal Chemistry 2016; 23 (15) . https://dx.doi.org/10.2174/0929867323666160405112954
DOI https://dx.doi.org/10.2174/0929867323666160405112954 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exploiting Protein Phosphatase Inhibitors Based on Cantharidin Analogues for Cancer Drug Discovery
Mini-Reviews in Medicinal Chemistry Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism A Squamous Cell Gallbladder Carcinoma: A Case Report and Literature Review
New Emirates Medical Journal Vitamin, Mineral, and Drug Absorption Following Bariatric Surgery
Current Drug Metabolism Sol-gel Encapsulation of Biomolecules and Cells for Medicinal Applications
Current Topics in Medicinal Chemistry The Genetic Background of Cholesterol Gallstone Formation: An Inventory of Human Lithogenic Genes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Effects of Cantharidin and Cantharidin Derivates on Tumour Cells
Anti-Cancer Agents in Medicinal Chemistry Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design MALAT1 Promotes Tumorigenesis and Increases Cellular Sensitivity to Herceptin in HER2-positive Breast Cancer
Current Cancer Drug Targets Systemic Treatment of Advanced Biliary Tract Carcinoma: Emerging Roles of Targeted Therapy and Molecular Profiling
Clinical Cancer Drugs Adiposity and the Gut - The Role of Gut Hormones
Current Nutrition & Food Science Editorial [Hot Topic: Molecular Targeted Therapy of Gastrointestinal Cancer (Guest Editor: Marcus W. Wiedmann)]
Current Cancer Drug Targets Enhanced Pro-Apoptotic Effect of Tetrandrine Loaded Nanoparticles Against Osteosarcoma Cells
Current Drug Delivery Molecular Bases of Chemoresistance in Cholangiocarcinoma
Current Drug Targets The Cross-over of Anticancer Agents with Osteoclast Activities
Current Cancer Therapy Reviews Diagnoses of Gastrointestinal Cancers After Gastrointestinal Bleeding in Patients Receiving Clopidogrel or Warfarin
Current Drug Safety Natural Product as Substrates of ABC Transporters: A Review
Recent Patents on Anti-Cancer Drug Discovery Membrane Targeted Chemotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis
Current Pharmaceutical Design Cystic Fibrosis, Vector-Mediated Gene Therapy, and Relevance of Toll-Like Receptors: A Review of Problems, Progress, and Possibilities
Current Gene Therapy Predicting Pediatric Drug Disposition-Present and Future Directions of Pediatric Physiologically-Based Pharmacokinetics
Drug Metabolism Letters